Abstract
全球结直肠癌每年新发病例数约120万,年病死人数超过60万,发病率居第3位,病死率居第4位[1].近些年,结直肠癌的发病率呈明显上升趋势[1].因此,结直肠癌的治疗一直是国内外学者研究的热点.随着靶向治疗药物表皮生长因子受体(EGFR)抑制剂西妥昔单抗(Cetuximab)和帕尼单抗(Panitumumab)的问世,结直肠癌的治疗进入了靶向治疗时代。
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Zhonghua bing li xue za zhi = Chinese journal of pathology
Paper Title
Journal
Date
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
